[
  {
    "ts": null,
    "headline": "FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease",
    "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
    "url": "https://finnhub.io/api/news?id=0cbd135b0a6421778065952940eea16e92d60fb7cf0daa412a3a700b00efe2d5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736795162,
      "headline": "FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease",
      "id": 132390187,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
      "url": "https://finnhub.io/api/news?id=0cbd135b0a6421778065952940eea16e92d60fb7cf0daa412a3a700b00efe2d5"
    }
  },
  {
    "ts": null,
    "headline": "FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
    "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
    "url": "https://finnhub.io/api/news?id=6a645ce79eb7bffd6136b408ff4a12084a9439be3077fd517f88168a1c2f97f2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736795105,
      "headline": "FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease",
      "id": 132390184,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration optionTOKYO and CAMBRIDGE, Mass., Jan. 13,...",
      "url": "https://finnhub.io/api/news?id=6a645ce79eb7bffd6136b408ff4a12084a9439be3077fd517f88168a1c2f97f2"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
    "summary": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
    "url": "https://finnhub.io/api/news?id=403461c3fdc542ef8c29a7a1aaadf9ed49bc62600769277add9a458c7fbf2d2c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736762160,
      "headline": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
      "id": 134161440,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Wants to Buy Its Partner Sage for Almost No Premium",
      "url": "https://finnhub.io/api/news?id=403461c3fdc542ef8c29a7a1aaadf9ed49bc62600769277add9a458c7fbf2d2c"
    }
  },
  {
    "ts": null,
    "headline": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
    "summary": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
    "url": "https://finnhub.io/api/news?id=6be856a556dea553ac3dab940f5d7b3eba909b860c862e0861af6c2195ca2cfb",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736750340,
      "headline": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
      "id": 132534962,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Sage Shares Surge Premarket After Biogen Proposes Takeover",
      "url": "https://finnhub.io/api/news?id=6be856a556dea553ac3dab940f5d7b3eba909b860c862e0861af6c2195ca2cfb"
    }
  }
]